^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    zavondemstat (TACH101)

    i
    Other names: TACH101, QC8222
    Company:
    Tachyon
    Drug class:
    KDM4 inhibitor
    over1year
    A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1, N=30, Active, not recruiting, Tachyon Therapeutics, Inc. | Recruiting --> Active, not recruiting | N=70 --> 30
    Enrollment closed • Enrollment change • Metastases
    |
    MSI (Microsatellite instability)
    |
    zavondemstat (TACH101)
    over1year
    A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1, N=70, Recruiting, Tachyon Therapeutics, Inc. | Phase classification: P1a/1b --> P1
    Phase classification • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    zavondemstat (TACH101)
    over2years
    TACH101, a first-in-class pan-inhibitor of KDM4 histone demethylase. (PubMed, Anticancer Drugs)
    A reduction in the population of tumor-initiating cells was observed following TACH101 treatment. Overall, these observations demonstrate the broad applicability of TACH101 as a potential anticancer agent and support its advancement into clinical trials.
    Journal • Epigenetic controller
    |
    DRD (DNA Repair Deficiency)
    |
    DDR • DRD
    |
    zavondemstat (TACH101)
    almost3years
    A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1a/1b, N=70, Recruiting, Tachyon Therapeutics, Inc. | Not yet recruiting --> Recruiting | Trial completion date: Mar 2024 --> Jul 2025 | Trial primary completion date: Jul 2023 --> Jul 2025
    Enrollment open • Trial completion date • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    zavondemstat (TACH101)
    almost3years
    A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1a/1b, N=70, Not yet recruiting, Tachyon Therapeutics, Inc. | Phase classification: P1 --> P1a/1b | Trial primary completion date: Nov 2023 --> Jul 2023
    Phase classification • Trial primary completion date • Metastases
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    zavondemstat (TACH101)
    4years
    A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of Oral TACH101 in Participants With Advanced or Metastatic Cancer (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Tachyon Therapeutics, Inc.
    Clinical • New P1 trial
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    zavondemstat (TACH101)
    over4years
    [VIRTUAL] Inhibition of histone lysine demethylases with TACH101, a first-in-class pan-inhibitor of KDM4. (ASCO 2021)
    Extensive preclinical work on TACH101 KDM4 inhibitor shows compelling data and broad applicability as a potential anti-cancer agent . Further evaluation is ongoing to advance the molecule into clinical trials.
    MSI (Microsatellite instability) • CD44 (CD44 Molecule)
    |
    MSI-H/dMMR
    |
    OncoPanel™ Assay
    |
    zavondemstat (TACH101)
    almost5years
    [VIRTUAL] TACH101, a first-in-class pan inhibitor of KDM4 histone lysine demethylases (AACR 2021)
    TACH101 is a potent pan inhibitor of KDM4 that is suggestive of broad potential in cancer treatment. Further preclinical evaluation is ongoing to advance the molecule into clinical trials.
    CD44 (CD44 Molecule)
    |
    OncoPanel™ Assay
    |
    zavondemstat (TACH101)